DBV Technologies S.A. (DBVT)

NASDAQ: DBVT · IEX Real-Time Price · USD
1.35
-0.03 (-2.17%)
Feb 7, 2023, 4:30 PM EST - Market closed
-2.17%
Market Cap 269.13M
Revenue (ttm) 9.73M
Net Income (ttm) -75.79M
Shares Out 199.36M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 137,989
Open 1.38
Previous Close 1.38
Day's Range 1.33 - 1.40
52-Week Range 1.08 - 3.43
Beta 1.24
Analysts Buy
Price Target 2.92 (+116.3%)
Earnings Date Mar 2, 2023

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 85
Stock Exchange NASDAQ
Ticker Symbol DBVT
Full Company Profile

Financial Performance

In 2021, DBVT's revenue was 5.71 million, a decrease of -49.38% compared to the previous year's 11.28 million. Losses were -97.81 million, -38.70% less than in 2020.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price forecast is $2.92, which is an increase of 116.30% from the latest price.

Price Target
$2.92
(116.30% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated Information Montrouge, France, January 23, 2023

2 weeks ago - GlobeNewsWire

DBV (DBVT) Up as FDA Lifts Partial Hold on Peanut Allergy Study

The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.

1 month ago - Zacks Investment Research

DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

Montrouge, France, December 23, 2022

1 month ago - GlobeNewsWire

DBV Technologies to Participate in Upcoming Investor Conference

Montrouge, France, November 22, 2022

2 months ago - GlobeNewsWire

DBV Technologies to Highlight New Clinical Data at ACAAI 2022

Montrouge, France, November 9, 2022

3 months ago - GlobeNewsWire

DBV Technologies Reports Third Quarter Financial Results and Business Update

Montrouge, France, November 3, 2022

3 months ago - GlobeNewsWire

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

Montrouge, France, October 31, 2022

3 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

NEW YORK , Oct. 10, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT).

4 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of DBV Technologies S.A. - DBVT

New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors ...

4 months ago - Newsfile Corp

DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold

DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA.

4 months ago - Zacks Investment Research

DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

Montrouge, France, September 21, 2022

4 months ago - GlobeNewsWire

DBV Technologies to Present at Upcoming Investor Conferences

Montrouge, France, September 2, 2022

5 months ago - GlobeNewsWire

Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?

Here is how DBV Technologies S.A. (DBVT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.

6 months ago - Zacks Investment Research

DBV Technologies Reports Second Quarter 2022 Financial Results

Montrouge, France, August 1, 2022

6 months ago - GlobeNewsWire

DBV Technologies to Participate in Upcoming EAACI 2022 Congress

Montrouge, France, June 28, 2022

8 months ago - GlobeNewsWire

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

Montrouge, France, June 16, 2022

8 months ago - GlobeNewsWire

Has DBV Technologies (DBVT) Outpaced Other Medical Stocks This Year?

Here is how DBV Technologies S.A. (DBVT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.

8 months ago - Zacks Investment Research

DBV Technologies Announces Private Placement Financing of $194 Million

Montrouge, France, June 9, 2022

8 months ago - GlobeNewsWire

HC Wainwright Says Viaskin Benefit Affirmed In Toddlers...What's Next?

HC Wainwright believes the most significant takeaway from DBV Technologies SA's (NASDAQ: DBVT) trial update was that 250ug treatment achieved the primary endpoint of difference between the percentage ...

8 months ago - Benzinga

DBV Technologies Shares Jump On Positive Data From Peanut Allergy Trial In Toddlers

DBV Technologies SA's (NASDAQ: DBVT) pivotal Phase 3 EPITOPE trial of Viaskin Peanut 250 µg for peanut-allergic toddlers ages 1 to 3 years met its primary endpoint.  Viaskin Peanut demonstrated a stat...

8 months ago - Benzinga

DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting

Montrouge, France, May 12, 2022

9 months ago - GlobeNewsWire